FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma

Trial

LOTIS-2

Drug

Zynlonta (loncastuximab tesirine-lpyl) · Anti-CD19 antibody-drug conjugate

Condition

Lymphoid